An assessment of the efficacy targets of drugs that represent an opportunity for targeted therapy is fundamental to the development of post-genomic research strategies within the pharmaceutical industry. Identification and validation of efficacy target is an important process in drug discovery and development. Extensive drug discovery efforts have yielded many approved and candidate drugs. Although sever drug databases provide the drug and their corresponding targets, there is an insufficient coverage of the clinical trial drugs over the past decades. Here, we conduct a comprehensive survey for current clinical trial drugs, therapeutic targets. The analysis contents include: 1) collect clinical trial drugs from different sources, 2) By analysis of the literature, we summarize the criteria for assign therapeutic targets for each drug based on its indication. The knowledge of these drugs and their targets is useful not only for drug discovery and development of targeted therapy, but also for facilitating the discovery of systems pharmacology.
but also for assisting the research of systems pharmacology [6] [7] designed at the discovery of multi-target drugs [8] and drug combinations [9] .
While there is an inadequate coverage of the number and the detailed information of clinical trial drugs in the established drug [10] , efficacy target [11] , pharmacology [12] , bioactive compound [13] , binding [14] , and pathway [15] databases ( Table 1 ). The shortage of the clinical trial drugs in these databases can be further revealed by the reported drug clinical trial success rates. For instance, among these databases, the previous version of the Therapeutic Target Database (TTD) contains the largest set of 3147 clinical trial drugs vs. 2003 approved drugs. The ratio of the approved and clinical trial drugs is 63.6%, which is much larger than the reported 6.6% -13.4% phase I clinical trial to drug approval success rates [16] . The update of Therapeutic Target Database (TTD) in 2016 increases markedly current and discontinued clinical trial drugs searchable from the literatures, public reports and clinical trial websites [17] , which can be proven by the number of targets have been reported in 2006 based on the number of innovative targets rates in 2002. 
Collection of Approved and Clinical Trial Drugs
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BindingDB [14] A database of experimentally determined protein-ligand binding affinities 0
KEGG [15]
A collection of databases dealing with genomes, biological pathways, diseases, drugs, and chemical substances 
Identification of the Primary Therapeutic Target(s)
Identification of the targets for approved drugs, drugs in clinical trial, and experimental agents is the most critical job. In order to identify the primary efficacy targets through which the drug mediates its clinical therapeutic activities, a comprehensive analysis of the literature for each drug is needed. The criteria for assignment were strict in that strong evidence of cell-based and/or in vivo evidence linking the target (and specific target subtype) to the effect of the drug must exist alongside binding data [1] [18] . Other criteria for potential drug targets must be related to the corresponding disease tested in clinic ( Figure 1 ). For monoclonal antibodies or recombinant proteins/peptides, their efficacy target(s) are relatively easy to assign because of their specificity.
The literature is often complex in terms of the information provided about efficacy targets. For cases in which a specific target is believed to be the sole or major route through which a drug achieves its efficacy, we accurately identified the drug against the single target at specific protein/mRNA subtype level, such as HER2 targeted by trastuzumab and mRNA of ApoB-100 targeted by mipomersen. For multi-target drugs, their targets were tentatively divided into the primary efficacy targets (play essential roles in the targeted disease) and the secondary targets (play facilitating roles such as drug bypass signaling in the disease). In the latest version of TTD, only the primary efficacy targets were identified and assigned as drug target. For example, INCB018424 is a dual inhibitor of Figure 1 . Criteria for assignment of therapeutic targets. both JAK1 and JAK2. About half of patients with myelofibrosis carry a gain-offunction mutation (V617F) in JAK2 gene that is the major contributor to the pathophysiology of this disease [19] . Thus, only JAK2 was identified as the primary efficacy target of INCB018424. Other than those targets of well-defined subtype, the remaining can be group into three categories. Firstly, some are imprecisely defined as targets with ambiguous subtype/subunit. For example, it is difficult to identify the specific target subtype/subunit for benzocaine, therefore the sodium channel was assigned as target of this drug. Secondly, for cases in which targets are imprecisely defined as target with ambiguous target species.
These targets are especially for infection related diseases. For example, teicoplanin is an antibiotic treating broad spectrum bacterial infections by inhibiting bacterial cell wall synthesis. Thirdly, the others targets are imprecisely defined as only to the pathway/biological process level. For example, the mode of action of tecfidera [20] is not clear so far. However, it was reported that this drug exerts its therapeutic effect by activating NRF2 pathway, thus, NRF2 pathway is imprecisely assigned as tecfidera's target.
There is a relatively small, but clinically significant, class of drugs that bind to DNA, or that have no an unknown or distinct mode of action. The literature changes frequently in terms of the knowledge available about drug indications and mechanisms of action, and so this information needs to be reviewed regularly.
Conclusion
The need for improved drug discovery productivity and innovation [21] [22] has led to intensifying efforts by employing advanced technologies [1] [2] [3] , novel therapeutic strategies such as RNA therapeutics and monoclonal antibodies, and the knowledge of target druggability features [23] , and the systems-level profiles [24] learnt from the studies of the approved and clinical trial drugs and targets.
The enriched information and search facilities in TTD complement the other established drug and target databases in promoting the drug discovery research.
